Founders Matt Lipscomb, Mike Lynch Operating Status Active Last Funding Type Series B Also Known As DMC Bio Legal Name DMC Biotechnologies, Inc. Company Type For Profit Phone Number (303) 210-2829 DMC Biotechnologies produces bio-based chemicals using fermentation. | DMC is a privately-held company, producing bio-based chemicals using fermentation. Cibus Enterprise has led a USD 34m Series B funding round in DMC alongside Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. SUSTAINABLE PRODUCTION Our L-alanine production in Europe will reduce CO2 emissions by over 90%, compared to imported L-alanine. DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. The round was led by Cibus Enterprise with investments from Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. DMC has gone commercial with DMC Biotechnologies, 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. Email us at news@bizwest.com.Notable rounds this week:Boulder-based DMC Biotechnologies completed the first close of its Series B funding round with $34 million. Biotechnology is revolutionising how everyday products are produced. DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million.DMC previously announced the first close of its Series B fundrais . Read Full Article Load More CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the completion of an oversubscribed and up-sized $215 million Series B financing. The objective of this study was to evaluate the bioavailability of DMC nutrients to typical urban landscape plants. Thermo Scientific RDE Series ULT Freezers. www.dmcbio.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Specialty Chemicals Other Industries Agricultural Chemicals Biotechnology Primary Office 2477 55th Street Suite 120 Boulder, CO 80301 United States DMC Biotechnologies Timeline 2019 2020 2021 2022 DMC TE (1) COLUMNEX LLC MS (1) ONTARIO CHEMICAL MS (1) Ultra Scientific (1) CHEMCO MANUFACTURING COMPANY INC.TE (1) LIFE TECHNOLOGIES (1) . It is important to note that both forecasts still show . Investors Number of Investors 9 Number of Partner Investors 1 Recent News That's equivalent to removing more than 60,000 cars from the road, annually. DMC Biotechnologies, Inc. 2,260 followers 3w Biotechnology has historically required exorbitant costs and timelines to commercialize. DMC Security Services, Inc. Midlothian, IL 60445 $13 - $15 an hour Part-time + 1 8 hour shift + 2 Patient Sitter Afternoons Contingent DMC Children's Hospital of Michigan 3.9 Detroit, MI 48201 (Medical Center area) +2 locations Under direct supervision, and according to established procedures, observes and monitors assigned patient (s) behavior. DMC Biotechnologies, Inc. | 1,787 followers on LinkedIn. Top investors include Solvay Ventures, Cibus Enterprise, Capricorn Partners, Sofinnova Partners,. Biotech 2014 DMC Biotechnologies edit_note Submit Changes Boulder, CO http://dmcbio.com/ DMC is a privately-held company, producing bio-based chemicals using fermentation. DMC Biotechnologies. Top investors include Solvay Ventures, Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures and Michelin. Location (s): Boulder CO United States Engineered microbial hosts using synthetic metabolic valves. . DMC represents Solvay Venture's first portfolio company in biotechnology. BizWest reports fundraisers by companies in Boulder, Broomfield, Larimer and Weld counties, DMC Biotechnologies, Inc.'s Post. DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures, and Michelin. Welcome to Funding Friday, BizWest's roundup of companies in Northern Colorado and the Boulder Valley kicking off fundraisers. Press release Document Solvay invests in DMC Biotechnologies to advance bio-based innovation (pdf) About Solvay About Solvay Ventures About DMC Biotechnologies Contact us 31 January 2022 - DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. Their novel, patent-pending technology for rapid engineering of robust microbial hosts enables the production of a broad diversity of specialty chemicals, flavors, fragrances . Jan. 31, 2022 Subsequent Close of Series B Financing, Total Raised $39 million 31 January 2022 - DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. Dynamic Metabolic Control (DMC) Biotechnologies, a U.S.-based biotechnology company, has received $34 million in the Series B funding round. In March 2003, DMC rates of 0, 9, 18, and 27 kg/m2 (0, 1.25, 2.5, 5 cm) were incorporated into the top 10 to 15 cm of Austin silty clay soil. Including this round, the Company has raised over $300 million to date. DMC Biotechnologies, Inc. announces that strategic investors Continental Grain Company, through their venture arm Conti Ventures, and Toyobo have joined the Series B fundraising round, bringing the total raised to $39 million. IXCELLS BIOTECHNOLOGIES USA MS (1) Nichiryo America (1) Gold Standard Diagnostics (1) Cibus Fund and Boulder Ventures are the most recent investors. DMC previously announced the first close of its Series B fundraising on 2 December 2021 with investment from Cibus . media@dmcbio.com About DMC DMC is a US bio-based chemical company that makes products using microbial fermentation. Many chemicals are too expensive today for broad market adoption, such as certain amino acids for animal feed or natural cleaning agents for personal care. These products can be made more affordably and . > more > All News All contents News: 1 On location DMC Biotechnologies has raised a total of $53M in funding over 5 rounds. For more information, visit: www.dmcbio.com EFFICIENCY Go from concept to commercial faster with our standardized, scalable, and proven technology platform. Find company research, competitor information, contact details & financial data for DMC Biotechnologies, Inc. of Boulder, CO. Get the latest business insights from Dun & Bradstreet. Avantor Services provides a wide range of specialized services and digital solutions to help you solve complex challenges. The support you need to optimize operations. DMC is leading the low cost, sustainable transformation of multiple product markets. For example, the LCS forecast projects General Fund revenues in FY 2022-23 to will be $17.95 billion compared to the OSPB forecast of $16.4 billion. DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) Company has a deep pipeline of predictable, scalable, cost-competitive products, addressing sustainability challenges across a wide range of industries Many chemicals are too expensive today for broad market adoption, such as certain amino acids for animal feed or natural cleaning agents for personal care. DMC Biotechnologies is funded by 10 investors. admin December 2, 2021 Leuven, Belgium: 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. DMC Biotechnologies, Inc. 10mo Report this post CEO Matt Lipscomb talks about our latest fundraise, what it means to DMC and sets it . Biotechnologies Receives $34 Million Series B Funding Cosmetics and Toiletries Top investors include Solvay Ventures, Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures and Michelin. In FY 2023-24, the LCS forecast projects General Fund revenues will be $18.06 billion compared to the OSPB forecast of $16.7 billion. 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. We've bui Site is running on IP address 8.192.172.77, host name 8.192.172.77 ( United States) ping response time 13ms Good ping.Current Global rank is 313,305, category rank is 2,251 . DMC Biotechnologies Closes $34M First Close of Series B Funding USA Published on December 3, 2021 DMC Biotechnologies, a Boulder, CO and Durham, NC-based biobased chemical company that. DMC Biotechnologies has developed its Dynamic Metabolic Control technology, a novel, low cost technology for rapid engineering of robust microbial hosts that enables the production of a broad diversity of specialty chemicals, flavors, fragrances, neutracueticals, natural products, pharmaceuticals, and APIs. Dmc.org is a Medicine website created by The Detroit Medical Center.This domain provided by networksolutions.com at 1994-03-09T05:00:00Z (28 Years, 62 Days ago), expired at 2024-03-10T05:00:00Z (1 Year, 304 Days left). Our precision fermentation process addresses the barriers. These produ . 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. The $34-million Series B funding round also includes Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures and Michelin. 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. The round was led by Cibus Enterprise with investments from Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin. DMC is commercial with its first product,. Explore DMC Biotechnologies's investment information, scientific platforms, therapeutic approaches, indications and more here! DMC is commercial with its first product, a bio-based chemical intermediate with primary applications in home . I am thrilled to share Capital on Tap has secured 100 million in funding to provide small businesses with a central hub to manage all aspects of. Funding Rounds Number of Funding Rounds 5 Total Funding Amount $53M Boulder-based DMC Biotechnologies completed the first close of its Series B funding round with $34 million. DMC Biotechnologies, 2 December 2021 - DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) with investment from Cibus Enterprise, Capricorn Partners, Sofinnova Partners, Breakthrough Energy Ventures, SCG, Boulder Ventures, Solvay Ventures and Michelin.. DMC is commercial with its first product, a bio-based chemical intermediate with . Their latest funding was raised on Dec 2, 2021 from a Series B round. DMC's proprietary technology platform simplifies the engineering of biology and makes fermentation more standardized, robust, and predictable. Simplifying biology for a sustainable future. 07-Dec-2021 - DMC Biotechnologies DMC Biotechnologies has completed the first close of its Series B fundraising, raising $34 million (USD) DMC's technology platform addresses the key barriers that have plagued the biotech industry for decades Photo by Avinash Kumar on Unsplash Dynamic Metabolic Control (DMC) Biotechnologies, a U.S.-based biotechnology company, has received $34 million in the Series B funding round. After months of training, on Sunday I completed the London Marathon in 3:53:33. SUPPLY CHAIN SECURITY DMC previously announced the first close of its Series B fundraising on 2 December 2021 with investment from Cibus . DMC Biotechnologies Announced Date Dec 2, 2021 Funding Type Series B Funding Stage Early Stage Venture Money Raised $39M Lead Investors Cibus Fund Cibus Fund invests in new technologies rapidly driving resource efficiency and sustainability across the food value chain. After more than a quarter century of investing in healthcare start-ups, Denis Lucquin, then the chairman of Sofinnova Partners, decided in the late 2000s that the time had come to explore the potential impact that biotechnology would have beyond healthcare. Crossing the line I was delighted to have beaten the four-hour mark. Liked by Archie Burgess. .